RIGEL PHARMACEUTICALS INC
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $294.3M | $179.3M | $116.9M | $120.2M | $149.2M |
| Operating income | $125.5M | $24.2M | -$20.5M | -$55.5M | -$12.5M |
| Cost of revenue | $19.6M | $18.6M | $7.1M | $1.7M | $1.1M |
| Cash from operations | $75.7M | $31.5M | -$5.7M | -$73.8M | $5.9M |
| Capital expenditure | — | — | — | $450,000 | $627,000 |
| Free cash flow | — | — | — | -$74.2M | $5.3M |
| Total assets | $513.6M | $164.0M | $117.2M | $134.3M | $167.3M |
| Total liabilities | $122.1M | $160.7M | $145.9M | $147.9M | $137.0M |
| Total debt | $52.5M | $60.0M | $60.0M | $40.0M | — |
Shares outstanding 18.5M · Free float 75.5%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.